SERUM ANTI-AGING PROTEIN - SIRTUIN 1 CONCENTRATION CORRELATES WITH IMPAIRED KIDNEY FUNCTION

Abstract

Objective: To compare serum concentration of sirtuin 1 between patients suffering from chronic kidney disease, conservatively treated and healthy volunteers. In addition, our aim was to establish its possible relation to kidney function, pharmacological treatment and demographic data. Design and method: Sirtuin 1 concentration was estimated in 102 patients suffering from stable chronic kidney disease and 26 healthy volunteers using commercially available assays. The correlation between sirtiuin 1 level, estimated glomerular filtration rate based on cystatin C, hypotensive therapy, statins use status, age and sex were analysed. Results: The median sirtuin 1 concentration in the study group was significantly higher than in the control group (2237.5 pg/mL vs 444.9 pg/mL, p < 0.001). Sirtuin 1 concentration positively correlated with CKD-EPI cystatin C eGFR (R = 0.51, p < 0.001), age (R = 0.23, p = 0.008), creatinine (R = 0.21, p = 0.038) and parathormone level (R = 0.26, p = 0.017). Statin and beta-blockers use were associated with decreased sirtuin concentration (p < 0.001 and p = 0.006, respectively). There were no differences in sirtuin 1 level between men and women (p = 0.779) Conclusions: Serum sirtuin 1 concentration was elevated in patients with chronic kidney disease and was dependent on the degree of kidney impairment. Statins and beta-blockers therapy was associated with decreased sirtuin 1 level. Patients with chronic kidney disease have excessive cardiovascular risk, which can be reduced by statins and beta-blockers use. Sirtuin 1 concentration may reflect high risk for cardiovascular disease. It could indicates individuals, who may benefit from more rigorous chronic kidney disease management. Further studies are warranted to establish if sirtuin 1 may become a novel, alternative marker of kidney function and cardiovascular risk.